Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Accepts sBLA Filing of Soliris® as a Potential Treatment for Patients with Refractory Generalize

americanpharmaceuticalreviewMarch 09, 2017

Tag: Soliris® , FDA , sibLA

PharmaSources Customer Service